Strong Buy
Buy
Hold
Sell
Strong Sell
Consensus
| Date | Grading Company | New Grade | Previous Grade | Action | Price When Posted | News Title | Publisher |
|---|---|---|---|---|---|---|---|
| 2026-01-08 | Piper Sandler | Neutral | Overweight | Downgrade | $13.775 | Ventyx Biosciences downgraded to Neutral from Overweight at… | TheFly |
| 2026-01-08 | Oppenheimer | Perform | Outperform | Downgrade | $13.73 | Ventyx Biosciences downgraded to Perform from Outperform at… | TheFly |
| 2026-01-08 | H.C. Wainwright | Neutral | Buy | Downgrade | $13.73 | Ventyx Biosciences downgraded to Neutral from Buy at H.C. W… | TheFly |
| 2026-01-08 | UBS | Neutral | Buy | Downgrade | $13.73 | Ventyx Biosciences downgraded to Neutral from Buy at UBS | TheFly |
| 2026-01-07 | UBS | Buy | N/A | Initialise | $10.05 | Ventyx Biosciences initiated with a Buy at UBS | TheFly |
| 2025-11-05 | H.C. Wainwright | Buy | Neutral | Upgrade | $8.09 | Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wai… | TheFly |
| 2025-10-27 | Oppenheimer | Outperform | Outperform | Hold | $5.81 | Ventyx Biosciences price target raised to $14 from $9 at Op… | TheFly |
| 2025-01-14 | H.C. Wainwright | Neutral | Neutral | Hold | $2.52 | Ventyx's Phase 2 programs 'high risk/high reward,' says H.C… | TheFly |
| 2024-10-16 | H.C. Wainwright | Neutral | Neutral | Hold | $2.41 | H.C. Wainwright Reiterates Neutral Rating on Ventyx Bioscie… | StreetInsider |
| 2024-09-24 | H.C. Wainwright | Neutral | Neutral | Hold | $2.46 | H.C. Wainwright Reiterates Neutral Rating on Ventyx Bioscie… | StreetInsider |